Get the content you want anytime you want.

The Contagion® Healthcare Associated Infections (HAI) specialty page provides HAI-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


ABSSSI: Standard Protocol of Admission and Treatment
Panelists share the typical presentation of an acute bacterial skin and skin structure infection patient in the emergency department and the standard protocol of IV antibiotics.
An Overview of ABSSSI
Peter L. Salgo, MD; Yoav Golan, MD; and Bruce M. Jones, PharmD, BCPS, identify the commonalities of ABSSSI, including the predominant pathogens, such as Staphylococcus aureus and Streptococcus, and gram-positive infections.
Fighting <i>Pseudomonas</i>: Impact On Patient Prognosis & Approaches to Combat Infection
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; Andrew Shorr, MD; Marin Hristos Kollef, MD; and Yoav Golan, MD, reflect on the impact that Pseudomonas infections have on patients’ prognoses and outline the basic treatment approaches they take to combat these infections.
Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy
Peter L. Salgo, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); Jason Pogue, PharmD, BCPS-AQID; Andrew Shorr, MD; and Debra Goff, PharmD, FCCP, reflect on the caveats in lipoglycopeptide therapy for gram-positive nosocomial infections and emphasize that this is a different, not overarchingly effective, class of drugs.
<i>Pseudomonas</i> Infections: Matching Causes and Prevention
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; Marin Hristos Kollef, MD; Andrew Shorr, MD; and Yoav Golan, MD, differentiate between pseudomonas colonization and infection, discussing important prevention methods regarding the causes of affliction.
<i>Pseudomonas</i> Infections in the ICU: Who's Susceptible?
Peter L. Salgo, MD; Marin Hristos Kollef, MD; Jason Pogue, PharmD, BCPS-AQID; Yoav Golan, MD; and Andrew Shorr, MD, identify which patients are most susceptible to Pseudomonas infections and address the settings in which risk for infection is greatest.
<i>C. difficile</i> Rates in the United Kingdom
Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.
Fecal Transplantation in <i>Clostridium difficile</i>
Lawrence J. Brandt, MD; Erik Dubberke, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, consider variables surrounding the use of fecal transplantation for the management of Clostridium difficile in select groups of patients.
Big advances in treatment can